



Molecular Biology and New Therapeutic Approaches to Cancer

Guest Editors:

Dr. Martin Vojtek

LAQV/REQUIMTE, Laboratory of
Pharmacology, Department of
Drug Sciences, Faculty of
Pharmacy, University of Porto,
4050-313 Porto, Portugal

Dr. Carmen Diniz

LAQV/REQUIMTE, Laboratory of
Pharmacology, Department of
Drug Sciences, Faculty of
Pharmacy, University of Porto,
4050-313 Porto, Portugal

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Cancer continues to pose a growing global health problem and is the second leading cause of death worldwide. Cancer is a heterogeneous group of malignancies with different prognosis and treatment considerations. This Special Issue aims to compile the latest advances in our understanding of cancer at the molecular level and to explore novel therapeutic strategies aimed at improving patient outcomes.

We encourage the submission of both review articles and original research papers (basic research and translational research) that highlight new therapeutic modalities, new drug leads and novel compounds, including targeted therapies, immunotherapies, and precision medicine approaches tailored to individual patients based on their molecular profiles.

We also welcome contributions that shed light on the intricate molecular pathways underlying cancer initiation, progression and metastasis, including current therapeutic challenges such as cancer cell drug resistance. This Special Issue also aims to address the dynamic interplay between components of the tumor microenvironment and cancer cell behavior at the molecular level to identify novel biomarkers and therapeutic targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)